November 2024

Contents

Editorial

• HTB news: i-Base changes during 2024

Special reports

• Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan

Conference reports

• Glasgow HIV Congress 2024: Introduction and links

• Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48

• EACS guidelines: New format and contents includes chemsex

• Double dose start for oral PrEP in new EACS guidelines – rapid protection in two hours

• Future PrEP and new results from PURPOSE 1 and 2 – does HIV exposure explain incident cases?

• Liverpool University Drug Interaction website recognised for global impact on research and care

• HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure

• Dolutegravir/lamivudine vs triple ART have similar efficacy in advanced HIV infection with CD4 <200 and viral load >100,000

Treatment access

• Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic

mpox (monkeypox)

• Mpox breakthrough cases after two doses of the MVA-BN vaccine

Coinfections and complications

• Bipolar disorder in people living with HIV

On the web

• WHO toolkit to strengthen engagement of health workers in emergency responses